Termination. On a Reversion Product-by-Reversion Product basis, # the Opt-Out Party will have the right to terminate this Agreement) in accordance with [Sections 16.3(a)(i), 16.3(a)(ii) and 16.3(a)(iii)])] (but, for clarity, not [Section 16.3(a)(iv)]) with respect to the applicable Reversion Product, and # the Continuing Party will have the right to terminate this Agreement upon written notice to the Opt-Out Party of the Continuing Party’s decision, its sole discretion, to cease permanently the Research, Development and Commercialization of such Reversion Product (which notice will be provided within ​ of the Continuing Party making such decision). In the event of a termination of this Agreement with respect to a Reversion Product, then the consequences in Section 16.5(b) will apply. For clarity, any termination of this Agreement with respect to a Reversion Product will result in the termination of the applicable Collaboration Antigen.

Exclusivity. The Parties’ respective obligations set forth in Section 10.8 will survive and continue to apply to a Reversion Product until the earlier of # such time as no further payments are owed by the Continuing Party to the Opt-Out Party for such Reversion Product in such country, # such time as the Continuing Party provides written notice to the Opt-Out Party of its decision, in its sole discretion, to cease permanently the Research, Development and Commercialization of such Reversion Product (which notice will be provided within ​ of the Opt-Out Party making such decision), and # the Opt-Out Party has terminated the Continuing Party’s license with respect to such Reversion Product as provided in Section 3.3(j). For clarity, Section 10.9 and Section 18.5(b) through Section 18.5(d) will continue to apply to the Reversion Product.